JPWO2023172906A5 - - Google Patents
Info
- Publication number
- JPWO2023172906A5 JPWO2023172906A5 JP2024553327A JP2024553327A JPWO2023172906A5 JP WO2023172906 A5 JPWO2023172906 A5 JP WO2023172906A5 JP 2024553327 A JP2024553327 A JP 2024553327A JP 2024553327 A JP2024553327 A JP 2024553327A JP WO2023172906 A5 JPWO2023172906 A5 JP WO2023172906A5
- Authority
- JP
- Japan
- Prior art keywords
- her2
- cancer
- antibody
- targeted
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263317472P | 2022-03-07 | 2022-03-07 | |
| US63/317,472 | 2022-03-07 | ||
| US202263329680P | 2022-04-11 | 2022-04-11 | |
| US63/329,680 | 2022-04-11 | ||
| PCT/US2023/063852 WO2023172906A1 (en) | 2022-03-07 | 2023-03-07 | Antibody drug conjugates comprising sting agonists, combinations and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025509266A JP2025509266A (ja) | 2025-04-11 |
| JP2025509266A5 JP2025509266A5 (https=) | 2026-03-13 |
| JPWO2023172906A5 true JPWO2023172906A5 (https=) | 2026-03-13 |
Family
ID=85800735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024553327A Pending JP2025509266A (ja) | 2022-03-07 | 2023-03-07 | Ｓｔｉｎｇアゴニストを含む抗体薬物コンジュゲート、組み合わせ、および使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230398229A1 (https=) |
| EP (1) | EP4489789A1 (https=) |
| JP (1) | JP2025509266A (https=) |
| KR (1) | KR20240150805A (https=) |
| CN (1) | CN119173277A (https=) |
| AU (1) | AU2023232820A1 (https=) |
| CA (1) | CA3245425A1 (https=) |
| IL (1) | IL315064A (https=) |
| MX (1) | MX2024010916A (https=) |
| TW (1) | TW202400241A (https=) |
| WO (1) | WO2023172906A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021202984A1 (en) | 2020-04-02 | 2021-10-07 | Mersana Therapeutics, Inc. | Antibody drug conjugates comprising sting agonists |
| WO2024192017A1 (en) * | 2023-03-13 | 2024-09-19 | Mersana Therapeutics, Inc. | Antibody drug conjugates comprising sting agonists, combinations and methods of use |
| WO2026043823A2 (en) * | 2024-08-19 | 2026-02-26 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI695011B (zh) | 2014-06-18 | 2020-06-01 | 美商梅爾莎納醫療公司 | 抗ｈｅｒ２表位之單株抗體及其使用之方法 |
| JP6991857B2 (ja) | 2014-10-10 | 2022-01-13 | イデラ ファーマシューティカルズ インコーポレイテッド | Ｔｌｒ９アゴニストをチェックポイント阻害剤と共に用いるがんの治療 |
| TW201834697A (zh) * | 2017-02-28 | 2018-10-01 | 美商梅爾莎納醫療公司 | Her2標靶抗體－藥物結合物之組合療法 |
| AU2020381495A1 (en) * | 2019-11-15 | 2022-05-19 | Seagen Inc. | Methods of treating HER2 positive breast cancer with tucatinib in combination with an anti-HER2 antibody-drug conjugate |
| WO2021202984A1 (en) * | 2020-04-02 | 2021-10-07 | Mersana Therapeutics, Inc. | Antibody drug conjugates comprising sting agonists |
-
2023
- 2023-03-07 MX MX2024010916A patent/MX2024010916A/es unknown
- 2023-03-07 CA CA3245425A patent/CA3245425A1/en active Pending
- 2023-03-07 JP JP2024553327A patent/JP2025509266A/ja active Pending
- 2023-03-07 KR KR1020247031618A patent/KR20240150805A/ko active Pending
- 2023-03-07 AU AU2023232820A patent/AU2023232820A1/en active Pending
- 2023-03-07 CN CN202380039134.1A patent/CN119173277A/zh active Pending
- 2023-03-07 US US18/179,699 patent/US20230398229A1/en active Pending
- 2023-03-07 TW TW112108211A patent/TW202400241A/zh unknown
- 2023-03-07 IL IL315064A patent/IL315064A/en unknown
- 2023-03-07 EP EP23714964.6A patent/EP4489789A1/en active Pending
- 2023-03-07 WO PCT/US2023/063852 patent/WO2023172906A1/en not_active Ceased